Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study

BMC Infectious Diseases

Hee Jin Cheong⁷  Woo Joo Kim⁷  Kyung Hwa Park¹  Jacob Lee⁸  Won Suk Choi³  Yu Mi Jo⁵  Jang Wook Sohn⁶  Young Keun Kim⁴  In-Gyu Bae⁹  Jin Soo Lee²  Jun Yong Choi^1,10  Joon Young Song⁷ 

[1] Division of Infectious Diseases, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea;Division of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea;Division of Infectious Disease, Department of Internal Medicine, Korea University Ansan Hospital, 123 Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do 425-707, Republic of Korea;Division of Infectious Diseases, Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Republic of Korea;Division of Infectious Diseases, Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Republic of Korea;Division of Infectious Disease, Department of Internal Medicine, Korea University Anam Hospital, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Republic of Korea;Asian Pacific Influenza Institute (APII), Seoul, Republic of Korea;Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea;Division of Infectious Diseases, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang, Republic of Korea;Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Yonsei, Seoul, Republic of Korea

关键词: Streptococcus pneumoniae;    Pneumococcal vaccines;    Pneumococcal infection;    Cost of illness;   

Others  :  1148612
DOI  :  10.1186/1471-2334-13-202

 received in 2012-12-30, accepted in 2013-04-14,  发布年份 2013

【 摘 要 】

Background

Streptococcus pneumoniae causes a broad spectrum of illnesses ranging from mild upper respiratory tract infections to invasive pneumococcal disease (IPD). Quantitative data on the burden of pneumococcal disease, important for the establishment of appropriate vaccination strategies, is currently lacking in adults.

Methods

This multicenter, retrospective cohort study was designed to estimate the clinical and economic burden of IPD in adults over the last decade. Data were collected from patients with IPD at 10 university hospitals in South Korea. We estimated the proportion of IPD among all hospitalized patients, the case fatality rate, and the direct medical costs of IPD. Data were further analyzed according to age and risk groups.

Results

During the study period, 970 patients with IPD were identified. The mean age for all patients was 60.9 years; patients aged 50–64 years (33.0%) were most numerous, followed by those aged 65–74 years (27.4%). Overall, the proportion of IPD was 0.36 cases/1000 hospitalized patients and the case fatality rate was 30.9%, which increased significantly with age (p < 0.01). The mean direct medical costs were estimated to be US $7,452 without a difference between age and risk groups. On multivariate analysis, old age, advanced ECOG performance status, bacteremic pneumonia, and nosocomial infection were independent risk factors of 30-day case fatality.

Conclusions

The clinical disease burden of IPD increased significantly with age and direct medical costs from IPD were substantial, regardless of age and co-morbid conditions. The current age-based vaccination strategy appears to be appropriate.

【 授权许可】

   
2013 Song et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

【 参考文献 】

• [1]WHO: Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Wkly Epidemiol Rec 2007, 82(12):93-104.
• [2]O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
• [3]Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP: Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011, 29(18):3398-3412.
• [4]Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morbidity and mortality weekly report 2012, 61(40):816-819.
• [5]Ledwich LJ, Harrington TM, Ayoub WT, Sartorius JA, Newman ED: Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert. Arthritis Rheum 2009, 61(11):1505-1510.
• [6]Pebody RG, Hippisley-Cox J, Harcourt S, Pringle M, Painter M, Smith G: Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999–2005. Epidemiol Infect 2008, 136(3):360-369.
• [7]Sowden E, Mitchell WS: An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007, 8:58. BioMed Central Full Text
• [8]Cho EY, Kang HM, Lee J, Kang JH, Choi EH, Lee HJ: Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine. J Korean Medical Sci 2012, 27(7):716-722.
• [9]Song JY, Cheong HJ, Heo JY, Noh JY, Seo YB, Kim IS, Choi WS, Kim WJ: Outpatientbased pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J 2013, 54:469-475.
• [10]Wikler MA: Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement Wayne. PA: Clinical and Laboratory Standards Institute; 2009.
• [11]Choi WS, Noh JY, Huh JY, Youn YK, Kim MJ, Jo YM, Kim JY, Song JY, Park DW, Kim WJ: Clinical features of invasive pneumococcal disease in Korea. Infect Chemother 2009, 42(3):156-161.
• [12]Laurichesse H, Romaszko JP, Nguyen LT, Souweine B, Poirier V, Guólon D, André M, Ruivard M, De Champs C, Caillaud D: Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dome, France, 1994–1998. Eur J Clin Microbiol Infect Dis 2001, 20(5):299-308.
• [13]Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA: Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010, 28(31):4955-4960.
• [14]Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L: Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza a (H1N1) virus–United States, 2009. Clin Infect Dis 2012, 54(9):1221-1229.
• [15]Barahona Rondon L, Soriano Garcia F, Granizo Martinez JJ, Santos O'Connor F, Lopez Duran JC, Fernandez Roblas R: Risk factors of mortality in invasive pneumococcal disease. Med Clin (Barc) 2004, 123(15):575-577.
• [16]Kang CI, Song JH, Kim SH, Chung DR, Peck KR, Thamlikitkul V, Wang H, So TM, Hsueh PR, Yasin RM: Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect 2013, 66(1):34-40.
• [17]Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E: Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009, 49(2):e23-29.
• [18]Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon S, Henriques-Normark B: Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42(4):451-459.
• [19]Rodríguez MA, González AV, Gavín MA, Martínez FM, Marín NG, Blázquez BR, Moreno JC: Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine 2011, 29(34):5740-5746.
• [20]Ritchie ND, Mitchell TJ, Evans TJ: What is different about serotype 1 pneumococci? Future microbiology 2012, 7(1):33-46.
• [21]Bravo LC: Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009, 27(52):7282-7291.
• [22]Centers for Disease Control and Prevention (CDC): Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998–2005. MMWR Morbidity and mortality weekly report 2008, 57(6):144-148.
• [23]Elberse KE, van der Heide HG, Witteveen S, van de Pol I, Schot CS, van der Ende A, Berbers GA, Schouls LM: Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine 2012, 30(52):7644-7651.
• [24]Lee S, Lee K, Kang Y, Bae S: Prevalence of serotype and multidrug-resistance of Streptococcus pneumoniae respiratory tract isolates in 265 adults and 36 children in Korea, 2002–2005. Microb Drug Resist 2010, 16(2):135-142.
• [25]Song JH, Baek JY, Cheong HS, Chung DR, Peck KR, Ko KS: Changes of serotype and genotype in Streptococcus pneumoniae isolates from a Korean hospital in 2007. Diagnostic microbiology and infectious disease 2009, 63(3):271-278.